Q2 2023 1 April - 30 June
Summary of the interim report
Net sales of 0.0 MSEK (3.7 MSEK)
Other income amounted to 0.3 MSEK (0.0 MSEK)
Second quarter of 2023
- R&D costs for the period amounted to 7.0 MSEK (14.7 MSEK)
- Profit after tax amounted to -10.1 MSEK (14.1 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -2.2 MSEK (-15.7 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 8.9 MSEK (7.3 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 60.6 MSEK (57.7 MSEK)
The period January-
- Net sales of 6.5 MSEK (3.7 MSEK)
- Other income amounted to 0.3 MSEK (0.4 MSEK)
- R&D costs for the period amounted to 15.6 MSEK (31.8 MSEK)
- Profit after tax amounted to -15.5 MSEK (-34.8 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -11.3 MSEK (-35.5 MSEK)
For more information, visit the
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is
Klaria (
https://news.cision.com/klaria-pharma-holding-ab/r/klaria-interim-report,c3823755
https://mb.cision.com/Main/12655/3823755/2253218.pdf
https://mb.cision.com/Public/12655/3823755/907dfd2270ab65da.pdf
(c) 2023 Cision. All rights reserved., source